The evidence on peptides — delivered weekly. Subscribe free →

Alpha-MSH

low risk

Also: α-Melanocyte Stimulating Hormone · ACTH(1-13) · Melanotropin

Moderate Evidence Research Only

Alpha-MSH is an endogenous melanocortin peptide from the pro-opiomelanocortin (POMC) precursor. Has broad anti-inflammatory properties, regulates skin pigmentation, suppresses appetite via MC4R, and provides neuroprotection. Precursor to Melanotan I and II pharmacology.

Molecular Weight
1664.9 Da
Formula
C76H100N18O19S
Common Dosing
Research only; not standardized for human use
Category
research
Last Reviewed
2025-01-15

Reported Benefits

Anti-inflammatory

Moderate Evidence 87 studies

Extensive evidence for peripheral and central anti-inflammatory effects; basis for melanocortin anti-inflammatory drug development.

Melanogenesis

Strong Evidence 120 studies

Foundational melanocyte biology. MC1R activation drives melanin synthesis — well-characterized.

Mechanism of Action

Endogenous agonist at MC1R (melanogenesis), MC3R (energy balance), MC4R (appetite suppression); activates anti-inflammatory pathways via NF-κB inhibition; reduces TNF-α, IL-6, IL-1β.

The Melanocortin System

Alpha-MSH is the endogenous reference point for the entire melanocortin drug class: Melanotan I (MC1R-selective), Melanotan II (non-selective), PT-141/Bremelanotide (MC3R/MC4R). Understanding α-MSH physiology clarifies why these drugs have their respective profiles.

✦ Sponsored

Stop Guessing About Your Health. Start Optimizing It.

Advanced diagnostics and licensed medical providers delivering personalized longevity care to uncover root causes, optimize health, and track progress virtually or in person.

Learn More →
Nava Health

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Not applicable as endogenous hormone

Contraindications

  • •N/A

Primary Uses

Anti-inflammatoryMelanogenesisAppetite suppressionNeuroprotection

Related Peptides

Melanotan IMelanotan IIPT-141

Planning a protocol?

Use the AI Stack Builder to generate a phased schedule, compatibility analysis, and monitoring checklist.

Stack Builder → Protocol Builder →

Weekly Briefing

Regulatory updates + new study breakdowns.

Related Articles

› PT-141 (Bremelanotide): What the RECONNECT Trials Showed and Who It's Actually For

For Practitioners

Do you prescribe Alpha-MSH?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.